Table 2 The Distribution of Age at Diagnosis in Thyroid Carcinoma Patients according to Demographic and Clinicopathological Characteristics
Variance | PTC | FTC | ||||
|---|---|---|---|---|---|---|
Mean ± SD, year | Median (QR), year | P valuea | Mean ± SD, year | Median (QR), year | P valuea | |
Sex | <.0001 | <.0001 | ||||
Male | 48.6 ± 14.3 | 48 (20) | 53.1 ± 14.5 | 54 (19) | ||
Female | 45.0 ± 14.1 | 44 (20) | 48.3 ± 16.0 | 48 (23) | ||
Race | <.0001 | .12 | ||||
White | 45.8 ± 14.3 | 45 (20) | 49.6 ± 15.7 | 50 (23) | ||
Black | 46.6 ± 13.7 | 45 (19) | 49.9 ± 15.0 | 50 (22) | ||
API | 45.7 ± 14.1 | 45 (21) | – | – | ||
AI/AN | 42.6 ± 14.5 | 40 (22) | 49.9 ± 16.2 | 49 (24) | ||
Unknown | 42.1 ± 13.3 | 41 (19) | 42.5 ± 14.1 | 40 (23) | ||
Tumor size (mean ± SD),mm | <.0001 | <.0001 | ||||
0–10 | 47.3 ± 13.3 | 47 (19) | 48.6 ± 13.9 | 50 (19) | ||
11–20 | 45.1 ± 13.7 | 44 (20) | 47.9 ± 14.9 | 47 (21) | ||
21–40 | 44.5 ± 15.0 | 43 (22) | 47.9 ± 15.1 | 48 (23) | ||
>40 | 46.0 ± 16.3 | 44 (24) | 52.9 ± 16.7 | 53 (26) | ||
Unknown | 47 ± 15.2 | 46 (22) | 51.5 ± 16.6 | 53 (27) | ||
ETE | <.0001 | <.0001 | ||||
Localized | 45.1 ± 13.8 | 44 (20) | 47.9 ± 15.1 | 48 (23) | ||
Minorb | 46.3 ± 14.7 | 46 (21) | 57.8 ± 16.4 | 57.5 (23) | ||
Strap musclesc | 46.5 ± 14.7 | 46 (22) | 53.5 ± 16.8 | 55 (26) | ||
Major neck structuresd | 53.2 ± 16.7 | 53 (26) | 61.3 ± 14.3 | 63 (17) | ||
Unknown | 47.1 ± 15.1 | 47 (23) | 60.0 ± 15.3 | 59 (24) | ||
Laterality | .49 | .72 | ||||
One side | 45.8 ± 14.2 | 45 (20) | 49.6 ± 15.7 | 50 (23) | ||
Bilateral | 46.4 ± 14.5 | 45 (21) | 52.5 ± 19.5 | 48.5 (33) | ||
Multifocality | .01 | <.0001 | ||||
Absent | 45.6 ± 14.5 | 45 (21) | 49.1 ± 15.7 | 49 (23) | ||
Present | 45.9 ± 13.9 | 45 (20) | 50.9 ± 15.4 | 51 (21) | ||
Unknown | 46.4 ± 15.1 | 45.5 (21) | 57.5 ± 15.9 | 57 (24) | ||
Histological Variant | <.0001 | – | ||||
Adenocarcinoma | 44.9 ± 14.3 | 44 (21) | – | – | ||
Follicular variant | 47.3 ± 13.9 | 47 (20) | – | – | ||
Oxyphilic cell variant | 47.6 ± 15.5 | 48.5 (23) | – | – | ||
Encapsulated variant | 46.0 ± 12.8 | 45 (19) | – | – | ||
Columnar cell variant | 50.5 ± 15.5 | 50 (23) | – | – | ||
Microcarcinomae | 47.7 ± 13.0 | 48 (19) | – | – | ||
Unknown | 45.0 ± 14.2 | 44 (20) | – | – | ||
T Stage | <.0001 | <.0001 | ||||
T1a | 47.2 ± 13.2 | 47 (19) | 48.8 ± 13.9 | 50 (18) | ||
T1b | 44.7 ± 13.6 | 44 (19) | 47.5 ± 15.0 | 47 (21) | ||
T2 | 43.5 ± 14.5 | 42 (21) | 47.3 ± 14.9 | 47 (22) | ||
T3 | 45.6 ± 15.0 | 45 (22) | 51.7 ± 16.6 | 52 (26) | ||
T4 | 53.2 ± 16.7 | 53 (26) | 61.3 ± 14.3 | 63 (17) | ||
Unknown | 45.6 ± 14.6 | 45 (21) | 50.4 ± 17.0 | 51 (27) | ||
Lymph node metastasis | <.0001 | <.0001 | ||||
Negative | 47.4 ± 13.6 | 47 (20) | 48.8 ± 15.5 | 49 (23) | ||
Positive | 43.8 ± 14.7 | 42 (22) | 55.3 ± 16.3 | 56 (24) | ||
Distant metastasisf | <.0001 | <.0001 | ||||
No | 45.7 ± 14.1 | 45 (20) | 48.8 ± 15.4 | 49 (23) | ||
Yes | 55.6 ± 17.2 | 58 (24) | 64.9 ± 13.0 | 67 (17) | ||
Unknown | 43.9 ± 14.9 | 43 (22) | 49.7 ± 16.9 | 48.5 (31) | ||
Total | 45.8 ± 14.2 | 45 (20) | 49.6 ± 15.7 | 50 (23) | ||